In an email letter sent last week – seen by Analytical Cannabis – the Department of Cannabis Control (DCC) reminded licensed labs that they are “required to accurately report testing results for cannabis batches.”
Cannabis consumers have higher levels of cadmium and lead in their blood than people who don’t consume the drug, according to a new study.
The US Department of Health and Human Services (HHS) has recommended that cannabis be reclassified from Schedule I to the less restrictive Schedule III within the Controlled Substance Act.
A significant minority of medical cannabis patients go on to develop cannabis use disorder (CUD), according to a new study. This proportion, however, is still lower than the proportion of recreational consumers with CUD.
One issue has come to divide the state’s legal cannabis industry in recent months: Aspergillus testing. Analytical Cannabis reached out to key figures on both side of the debate to find out why fungi testing has become so fraught.
Heavy metals expert Robert Thomas previews his new book, the 4th Edition of Practical Guide to ICP-MS and Other Atomic Spectroscopy Techniques: A Tutorial for Beginners.
Cannabis and hallucinogens are more popular than ever in the US, according to an ongoing National Institutes of Health (NIH) survey.
Researchers gave the ‘magic mushroom’ drug to ten participants with anorexia, who then received follow-up psychological support.
In the second episode of Analytical Cannabis' new video series, The Cannabis Industry Needs..., A2LA's Morgan Keefer explains why the the industry can benefit from more stringent proficiency testing and regular interlaboratory check-ins.